Hints and tips:
Related Special Reports
...Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma....
...The addition of Amazon Pharmacy to Eli Lilly’s direct-to-consumer dispensing network is the first time Amazon has partnered with a big drug company since it launched its online pharmacy business in 2020....
...Not only are other pharma groups scrambling to buy up biotechs with promising obesity drugs, but Eli Lilly and Novo Nordisk also are putting the drugs to work on other disease areas....
...The US drug regulator has delayed an approval decision on Eli Lilly’s promising Alzheimer’s disease drug, which was expected to be greenlit this month....
...According to the Health Transformation Alliance, a co-operative of American employers seeking cheaper healthcare, the use of anti-obesity drugs among its members was 64 per cent higher in 2023 than in 2022...
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...Meanwhile Eli Lilly last year bought Versanis, a biotech developing an antibody treatment that aims to preserve muscle mass in patients taking weight-loss drugs....
...Dear reader, It isn’t often that a company pays good money to criticise customers for buying its product. But that is what Eli Lilly did this week....
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
...After the MHRA announced authorisation of Eli Lilly’s “KwikPen” on Thursday, a format that provides four doses in one device, the company has said it will now be able to supply the drug to England, Scotland...
...High demand for weight-loss drugs has helped Novo Nordisk become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s largest pharmaceutical company...
...Eli Lilly has called for competition regulators to scrutinise an $11bn deal by its main competitor Novo Nordisk to snap up additional manufacturing capacity, as the rivalry between the drugmakers to dominate...
...They include the popular new diabetes and weight-loss drugs Ozempic and Wegovy, made by Novo Nordisk, and Mounjaro and Zepbound made by Eli Lilly....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...Regulators on both sides of the Atlantic have cleared Eli Lilly’s injectable diabetes medication for use as a weight loss treatment, creating the first direct rival to Wegovy, Novo Nordisk’s obesity drug...
...Highlighting continued caution from regulators, the agency last month delayed an approval decision on donanemab, Eli Lilly’s Alzheimer’s drug....
...Indianapolis-based Eli Lilly, meanwhile, has become the world’s largest pharmaceutical company on the back of sales of its drug Mounjaro for diabetes and strong trial results for its use in weight loss....
...Hassabis stated the goal days after announcing Isomorphic Lab’s first two pharmaceutical partnerships with Eli Lilly and Novartis, which came to a combined value of up to $3bn, in deals set to transform...
...The US federal drug regulator has approved Eli Lilly’s injectable diabetes medication for weight loss, as demand for the blockbuster treatments continues to surge....
...Both Leqembi and Eli Lilly’s new drug donanemab target amyloid, a toxic protein that builds up in the brain, usually before significant levels of tau develop....
...Sales of Mounjaro, Lilly’s drug for diabetes that is also used off-label for weight loss, were $1.4bn....
...This is a very small deal for a company as big as Eli Lilly. The drugs giant is riding high on diabetes drug Mounjaro, which has potential use as a weight-loss treatment....
...Eli Lilly, the world’s largest drugmaker, plans to bolster its portfolio of cancer drugs by buying Point Biopharma for $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price....
...US drugmaker Eli Lilly is riding a wave of investor optimism and media hype about new treatments for two of the biggest public health problems: obesity and Alzheimer’s....
International Edition